## Supporting Information

## For

## Sustainable Methine Sources for the Synthesis of Heterocycles under Metal- and Peroxide-Free Conditions

Gopal Chandru Senadi, <sup> $a,\pm, \pm$ </sup> Vishal Suresh Kudale, <sup> $a,\pm$ </sup> and Jeh-Jeng Wang<sup>\*,a,b</sup>

<sup>±</sup> *These two authors contributed equally.* 

<sup>*a*</sup> Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, No. 100, Shih-Chuan 1<sup>st</sup> Rd, Sanmin district, Kaohsiung City, 807 (Taiwan).

<sup>b</sup>Department of Medical Research, Kaohsiung Medical University Hospital, No. 100, Tzyou 1<sup>st</sup> Rd, Sanmin District, Kaohsiung City, 807 (Taiwan).

<sup>+</sup> Present addresses: Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur, Chennai - 603203, India

E-mail: jjwang@kmu.edu.tw.


## **Table of Contents**


1)	General Information	<b>S</b> 3
2)	General Procedures	S3-S7
3)	Spectral Characterizations	S8-S16
4)	Kinetic Studies	S17-S21
5)	Benzimidazole Mechanism	S22
6)	1,4-Dioxane Mechanism	S23
7)	X-ray Analysis	S24-S25
8)	References	S26- S27
9)	Copies of <sup>1</sup> H & <sup>13</sup> C	S28-S72

#### (1) General Information

<sup>1</sup>H, <sup>13</sup>C and DEPT NMR spectra were recorded on a 400 MHz Varian Unity Plus or Varian Mercury plus spectrometer. The chemical shift (δ) values are reported in parts per million (ppm), and the coupling constants (J) are given in Hz. The spectra were recorded using CDCl<sub>3</sub> as a solvent. <sup>1</sup> H NMR chemical shifts are referenced to tetramethylsilane (TMS) (0 ppm). <sup>13</sup>C NMR was referenced to CDCl<sub>3</sub> (77.0 ppm) or DMSO-d<sub>6</sub> (39.51 ppm). The abbreviations used are as follows: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublet; ddd, doublet of doublet of doublet; dt, doublet of triplets; td, triplet of doublet; m, multiplet. Mass spectra and high resolution mass spectra (HRMS) were measured using the ESI (FT-MS solariX) at National Sun Yat-Sen University, Kaohsiung, Taiwan. Melting points were determined on an EZ-Melt (Automated melting point apparatus). All products reported showed <sup>1</sup>H NMR spectra in agreement with the assigned structures. Reaction progress and product mixtures were routinely monitored by TLC using Merck TLC aluminum sheets (silica gel 60 F254). Column chromatography was carried out with 230–400 mesh silica gel 60 (Merck) and a mixture of hexane/ethyl acetate or hexane as an eluent. Preparative TLC was run on a Merck TLC aluminum sheets (silica gel 60 F254).


#### (2) Experimental Procedures






To a stirred solution of Isatoic anhydride (S1, 1.2 mol) in DMF (10 mL) was added aniline derivatives (S2, 1.2 mmol) and stirred at 80 °C for 8 ~ 24 h. After the completion of the reaction by TLC chromatogram, the reaction mixture was cooled to room temperature and diluted with ice water (60 mL) followed by extraction with ethyl acetate (3X20 mL). The obtained organic layer was partitioned between saturated brine solutions (20 mL) and dried over Na<sub>2</sub>SO<sub>4</sub> followed by concentration under rotary vacuum. The obtained crude was purified using column chromatography by eluting 8-15% of ethylene acetate (EA)/hexane (HEX) to afford the pure 2-amino-*N*-phenylbenzamides **1a-r & t, 1s, 1e'** in 60%-80% yields.

#### (ii) General Experimental Procedure (B) for Synthesis of 2-Amino-N-phenylbenzamides:<sup>2</sup>



To a stirred solution of anthranilic acid (S3, 1.2 mmol) in dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>) (3.0 mL) was added EDC.HCl (1.2 mmol), HOBt (1.2 mmol) and aniline derivatives (S2, 1.2 mmol) followed by the dropwise addition of DIPEA (2.5 mmol). The reaction mixture was allowed to stir at room temperature until the completion of reaction was monitored by TLC (24 ~ 36 h). After completion, the reaction mixture was diluted with ice water (10 mL) followed by the extraction with EA (3X20 mL). The combined organic layer was washed with 1N HC1 (15 mL) followed by saturated brine solution, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under rotary vacuum. The obtained crude was purified using column chromatography by eluting 8-15% of EA/HEX to afford the pure 2-amino-*N*-phenylbenzamides 1v-z & 1a'-d', 1f'in 50%-65% yields.


(iii) General Experimental Procedure (C) and Spectral Characterization for the Synthesis of Quinazolin-4(3*H*)-ones with Ethylene Glycol (EG) as "–CH-" Source



To an oven dried sealed tube was charged with **1a-1f' or 3 or 4** (0.15 mmol), ethylene glycol (EG): H<sub>2</sub>O (9:1) (0.25 M) and TsOH. H<sub>2</sub>O (0.15 mmol) and allowed to stir at 110° C until the completion of reaction (4 ~ 36 h) by TLC. After completion, the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated


under reduced pressure to get the crude compound. The obtained crude was purified using column chromatography by eluting from hexane to 20% ethyl acetate/hexane to afford pure quinazolin-4(3*H*)-ones **2a**-2f' in 71%-96% yields.

(iv) General Experimental Procedure (D) and Spectral Characterization for the Synthesis of Benzimidazoles using 2-methoxyethanol as "-CH-" source




To an oven dried sealed tube was charged **5** (0.15 mmol), 2-methoxyethanol: H<sub>2</sub>O (9:1) (0.25 M) and TsOH. H<sub>2</sub>O (0.15 mmol) and allowed to stir at 110° C until the completion of reaction (8 ~ 16 h) by TLC. After completion, the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude was purified using column chromatography by eluting from hexane to 50 % ethyl acetate/hexane to afford pure benzimidazoles **6a-g** in 74%-87% yields.

(v) General Experimental Procedure (E) and Spectral Characterization for the Synthesis of Quinazolin-4(*3H*)-ones with Propargyl alcohol as "–CH-" Source




To an oven dried sealed tube was charged **1a-1u** (0.15 mmol), Propargyl alcohol (0.25 M) and TsOH. H<sub>2</sub>O (0.15 mmol) and allowed to stir at  $110^{\circ}$  C until the completion of reaction (4 h) by TLC. After completion, the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude was purified using column chromatography by eluting from hexane to 20 % ethyl acetate/hexane to afford pure quinazolin-4(3*H*)-ones **2f**, **k**, **m**, **n**, **q**, **r**, **u** in 73%-96% yields.

# (vi) General Experimental Procedure (F) and Spectral Characterization for the Synthesis of Quinazolin-4(3*H*)-ones with 1, 4-Dioxane as "–CH-" Source



To an oven dried sealed tube was charged **1a-1f'** (0.15 mmol), 1, 4-dioxane (0.25 M) and TsOH. H<sub>2</sub>O (0.15 mmol) and allowed to stir at 110 °C until the completion of reaction (4 ~ 36 h) by TLC. After completion, the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude was purified using column chromatography by eluting from hexane to 20 % ethyl acetate/hexane to afford pure quinazolin-4(3*H*)-ones **2a,b,d-l,o-t,v-z,2a'-d-,f'** in 53%-90% yields.


#### Scheme S1. Scope of *o*-amino benzamide derivatives with 1, 4-Dioxane <sup>a,b</sup>



<sup>*a*</sup> Reaction conditions: Compound **1** (0.15 mmol), TsOH.H<sub>2</sub>O (1.0 equiv) and 1,4-Dioxane (0.25 M) were stirred at 110 °C in the presence of O<sub>2</sub> balloon for 4 - 36 h. <sup>*b*</sup> Isolated yields.

#### (3) Spectral Characterization

3-phenylquinazolin-4(3H)-one (2a):<sup>3</sup> The title compound was prepared according to the general procedure C



on a 0.15 mmol scale to obtain as a white solid (32 mg, yield = 96%); Mp. 132-140 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.38 (ddd, *J* = 7.6, 1.2, 0.4 Hz, 1H), 8.14 (s, 1H), 7.82-7.77 (m, 2H), 7.58-7.54 (m, 3H), 7.52-7.50 (m, 1H), 7.45-7.42 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.75, 147.85, 146.06, 137.46, 134.58, 129.63, 129.10, 127.64,

127.56, 127.17, 126.98, 122.36.

**3-(***p***-tolyl)quinazolin-4(3***H***)-one (2b):<sup>3</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a light yellow solid (31 mg, yield = 88%); Mp.172-174 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) \delta 8.36-8.34 (m, 1H), 8.10 (s, 1H), 7.78-7.73 (m, 2H), 7.53 (ddd,** *J* **= 8.0, 6.8, 1.6 Hz, 1H), 7.34-7.27 (m, 4H), 2.42 (s, 3H); <sup>13</sup>C NMR** 

(CDCl<sub>3</sub>, 100 MHz); δ 160.80, 147.84, 146.22, 139.14, 134.85, 134.42, 130.15, 127.49, 127.47, 127.09, 126.66, 122.33, 21.13.

**3-(2,4-dimethylphenyl)quinazolin-4(3***H***)-one (2c)**:<sup>4</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a light brown solid (31 mg, yield = 82%); Mp.81-83 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.37 (ddd, *J* = 8.0, 2.0, 1.2 Hz, 1H) 7.98 (s, 1H), 7.82-7.76 (m, 2H), 7.54 (ddd, *J* = 8.0, 6.4, 1.2 Hz, 1H), 7.20-719 (m, 1H), 7.14-7.11 (m,2H), 2.39 (s, 3H), 2.15 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.55, 148.05, 146.56, 139.74, 135.32, 134.44, 134.00, 131.96, 127.91, 127.50, 127.47, 127.12, 122.38, 21.09, 17.58.

**3-(2-methoxyphenyl)quinazolin-4**(*3H*)-one (2d):<sup>5</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as alight yellow solid (34 mg, yield = 90%); Mp.144-146 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.38-8.36 (m, 1H), 7.98 (s, 1H), 7.82-7.76 (m, 2H), 7.54-7.46 (m, 2H), 7.35 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.13-7.08 (ddd, *J* = 10.4, 7.6, 1.2 Hz, 2H), 3.81 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.62, 154.62, 148.00,

147.15, 134.34, 130.89, 129.09, 127.44, 127.25, 127.12, 125.92, 122.64, 120.94, 112.21, 55.79.


**3-(3-methoxyphenyl)quinazolin-4(3***H***)-one (2e)**:<sup>3</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a white solid (34 mg, yield = 90%); Mp.151-153 °C; <sup>1</sup>H NMR(CDCl<sub>3</sub>, 400 MHz) δ 8.39-8.36 (m, 1H), 8.13 (s, 1H), 7.81-7.78 (m, 2H), 7.56 (ddd, *J* = 8.0, 6.8, 1.2 Hz, 1H), 7.45 (t, *J* = 8.4 Hz, 1H), 7.04 (ddd, *J* = 8.4, 2.4, 0.4 Hz, 1H), 6.98-6.96 (m, 2H), 3.85 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 160.67, 160.39, 147.79, 146.03, 138.47, 134.55, 130.36, 127.61, 127.54, 127.15, 122.34, 119.06, 115.03, 112.80, 55.52.

**3-(4-methoxyphenyl)quinazolin-4(3H)-one (2f)**.<sup>3</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a light yellow solid (35mg, yield =O Ö 93%); Mp.181-183 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.38 (ddd, J = 8.0, 0.4, 1.2 Hz, 1 2f 1H), 8.11 (s, 1H), 7.82-7.75 (m, 2H), 7.54 (ddd, J = 8.0, 6.8, 1.6 Hz, 1H), 7.35-7.26 (m, 2H), 7.06-7.03 (m, 2H), 3.87 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 160.93, 159.82, 147.81, 146.35, 134.39,

130.08, 128.05, 127.47, 127.44, 127.05, 122.28, 114.73, 55.51.

3-(3,4,5-trimethoxyphenyl)quinazolin-4(3H)-one (2g):<sup>6</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a light yellow solid (38 mg, 0´ О. yield = 79%); Mp.139-141 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.36 (dd, J = 8.0, 1.2) 0 Hz, 1H), 8.12 (s, 1H), 7.83-7.75 (m, 2H), 7.56 (ddd, J = 8.0, 6.8, 1.4 Hz, 1H), 6.62 (s, 2g 2H), 3.88 (d, J = 9.2 Hz, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.84, 153.76, 147.74,

146.06, 138.42, 134.60, 132.95, 127.66, 127.53, 127.07, 122.21, 104.59, 60.86, 56.26.




procedure C on a 0.15 mmol scale to obtain as a white solid (30 mg, yield = 83%); Mp.199-201 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.36 (dd, J = 8.0, 1.2 Hz, 1H), 8.10 (s, 1H), 7.83-7.76 (m, 2H), 7.56 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.43-7.40 (m, 2H),

7.27-7.22 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  163.84, 161.35 (d,  $J_F$ =248.2 Hz), 160.78, 147.81, 145.81, 134.69, 133.37 (d,  $J_F$ =3.0 Hz), 128.93, 128.84 (d,  $J_F$ =8.7 Hz), 127.77, 127.63, 127.15, 122.24, 116.78, 116.55, (d.  $J_F$ =23.2 Hz).

**3-(4-chlorophenyl)quinazolin-4(3H)-one (2i)**<sup>5</sup> The title compound was prepared according to the general CI procedure C on a 0.15 mmol scale to obtain as a white solid (33 mg, yield = 86%); 0 Mp.138-140 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.36 (ddd, J = 7.6, 1.2, 0.4 Hz, 1H), N 8.10 (s, 1H), 7.84-7.76 (m, 2H), 7.58-7.52 (m, 3H), 7.41-7.37 (m, 2H); <sup>13</sup>C NMR 2i (CDCl<sub>3</sub>, 100 MHz) & 160.55, 147.70, 145.50, 135.82, 135.09, 134.69, 129.80, 128.28, 127.77, 127.61, 127.11,

122.14.


**3-(4-bromophenyl)quinazolin-4(3H)-one (2i)**:<sup>3</sup> The title compound was prepared according to the general



procedure C on a 0.15 mmol scale to obtain as a white solid (39 mg, yield = 87%); Mp.186-188 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.35 (ddd, J = 8.0, 1.4, 0.5 Hz, 1H), 8.07 (s, 1H), 7.80-7.77 (m, 2H), 7.68-7.66 (m, 2H), 7.55 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.33-7.29 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 160.50, 147.72, 145.43,

136.37, 134.72, 132.81, 128.58, 127.80, 127.64, 127.14, 123.13, 122.17.


**3-benzylquinazolin-4(3H)-one (2k)**:<sup>3</sup> The title compound was prepared according to the general procedure C



on a 0.15 mmol scale to obtain as a white solid (31 mg, yield = 88%); Mp.114-116 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.33 (dd, J = 8.0 1.2, Hz, 1H), 8.11 (s, 1H), 7.78-7.69 (m, 2H), 7.51 (ddd, J = 8.8, 7.2, 1.2, Hz, 1H), 7.36-7.30 (m, 5H), 5.19 (s, 2H); <sup>13</sup>C NMR

(CDCl<sub>3</sub>, 100 MHz) & 161.02, 147.99, 146.28, 135.68, 134.25, 128.98, 128.26, 127.95, 127.47, 127.33, 126.84, 122.17, 49.55.

**3-(4-methoxybenzyl)quinazolin-4(3H)-one (2l)**<sup>?</sup> The title compound was prepared according to the general



procedure C on a 0.15 mmol scale to obtain as a light yellow solid (32 mg, yield = 81%); Mp.123-125 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.31 (dd, J = 8.0, 1.2 Hz, 1H), 8.09 (s, 1H), 7.76-7.67 (m, 2H), 7.49 (ddd, J = 8.8, 6.8, 1.2 Hz, 1H), 7.31-

7.29 (m, 2H), 6.88-6.85 (m, 2H), 5.12 (s, 2H), 3.77 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 161.04, 159.56, 147.98, 146.24, 134.20, 129.57, 127.77, 127.43, 127.28, 126.81, 122.19, 114.35, 55.27, 49.17.

**3-ethylquinazolin-4(3H)-one (2m)**:<sup>8</sup> The title compound was prepared according to the general procedure C on Ο N 2m


a 0.15 mmol scale to obtain as alight yellow solid (19 mg, yield = 73%); Mp.72-74 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.33 (ddd, J = 8.0, 1.6, 0.4 Hz, 1H), 8.06 (s, 1H), 7.78-7.70 (m, 2H), 7.51 (ddd, *J* = 8.0, 6.8, 1.2 Hz, 1H), 4.08 (q, *J* = 7.2 Hz, 2H), 1.43 (t, *J* = 7.2 Hz, 3H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 160.86, 148.08, 146.21, 134.06, 127.32, 127.16, 126.57, 122.12, 42.05, 14.82.

**3-propylquinazolin-4(3H)-one (2n)**:<sup>9</sup> The title compound was prepared according to the general procedure C 0 on a 0.15 mmol scale to obtain as a light brown solid (25 mg, yield = 89%); Mp.73-75 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.32 (ddd, J = 8.0, 1.2, 0.8 Hz, 1H), 8.03 (s, 1H), 7.78-7.69 2n (m, 2H), 7.50 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 3.99-3.95 (m, 2H), 1.88-1.79 (m, 2H), 1.01 (t, J = 7.6 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  161.03, 148.06, 146.58, 134.10, 127.34, 127.18, 126.66,

122.14, 48.56, 22.61, 11.10.

**3-butylquinazolin-4(3H)-one (20)**<sup>10</sup> The title compound was prepared according to the general procedure C on



a 0.15 mmol scale to obtain as a light brown solid (22 mg, yield = 71%); Mp.59-61 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.33 (dd, J = 8.0, 1.2 Hz, 1H) 8.04 (s, 1H), 7.78-7.70 (m, 2H), 7.51 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 4.01 (t, J = 7.2 Hz, 2H), 1.83-1.75 (m, 2H),

1.45-1.40 (m, 2H) 0.99 (t, J = 7.2 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  161.01, 148.06, 146.53, 134.06, 127.33, 127.15, 126.63, 122.14, 46.75, 31.37, 19.84, 13.59.

**3-(adamantan-1-yl)quinazolin-4(3***H***)-one (2p)**: The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a white solid (32 mg, yield = 76%); Mp.203-205 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.27 (dd, *J* = 6.2, 2.0 Hz, 2H), 7.74-7.70 (m, 1H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.48-7.44 (m, 1H), 2.46 (d, *J* = 2.4 Hz, 6H), 2.88 (s, 3H), 1.84-1.76 (m, 6H), 1.69 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  162.03, 146.93, 143.91, 133.88, 126.83,

5H), 1.84-1.76 (m, 6H), 1.69 (s, 1H); <sup>14</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) 8 162.05, 146.95, 145.91, 155.88, 126.85, 126.69, 126.67, 123.15, 62.48, 39.87, 35.99, 29.99; HRMS (ESI): Calc'd for  $[M+H]^+$  C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O : 281.1649; found 281.1648.

**3-allylquinazolin-4**(*3H*)-one (2q):<sup>11</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a light brown solid (20 mg, yield = 73%); Mp. 54-56 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.33 ( dd, *J* = 8.0, 1.6 Hz, 1H ), 8.02 (s, 1H), 7.79-7.71 (m, 2H), 7.52 (ddd, *J* = 8.0, 6.8, 1.2 Hz, 1H), 6.05-5.95 (m, 1H), 5.32-5.25 (m, 2H), 4.65 (dt, *J* =1.6, 5.6 Hz, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.74, 147.97, 146.15, 134.22, 131.76, 127.40, 127.28,

126.72, 122.01, 118.80, 48.27.

**3-(prop-2-yn-1-yl) quinazolin-4(3***H***)-one (2<b>r**):<sup>12</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a white solid (21 mg, yield = 77%); Mp.114-115 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.31 (dd, *J* = 0.8, 8.0 Hz, 2H), 7.78 (ddd, *J* = 1.6, 7.2, 8.4 Hz, 1H), 7.73 (dd, *J* = 1.2, 8.4 Hz, 1H), 7.52 (ddd, *J* = 8.4, 7.6, 1.6 Hz, 1H), 4.83 (d, *J* = 2.8, 2H), 2.51 (t, *J* = 2.4 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.32, 147.83, 144.97, 134.46, 127.52, 127.48, 126.72, 126.60, 121.68, 75.08, 35.14.

**3-(2-hydroxyethyl) quinazolin-4(3***H***)-one (2s):** The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a white solid (26 mg, yield = 78%); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.31 (ddd, *J* = 8.0, 1.6, 0.4 Hz, 1H), 8.06 ( s, 1H), 7.77-770 (m, 2H), 7.52 (ddd, *J* = 8.4, 6.8, 1.6 Hz, 1H), 4.07 (t, *J* = 7.2 Hz, 2H), 3.73 (t, *J* = 6.0 Hz 2H), 1.94-1.90 (m, 2H), 1.76 (s, 1H), 1.69-1.64 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  161.12, 147.88, 146.53, 134.20, 127.27, 127.22, 126.56, 121.92, 61.85, 46.73, 29.26, 26.01:HRMS (ESI): Calc'd for [M+H]<sup>+</sup> C<sub>12</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub> : 219.11280; found 219.11304.


**3-methoxyquinazolin-4**(*3H*)-one (2t): The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a light yellow solid (20 mg, yield = 75%); Mp.182-184 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.35 (ddd, *J* = 8.0, 1.2, 0.4 Hz, 1H), 8.26 (s, 1H), 7.79-7.74 (m, 2H), 7.55 (ddd, *J* = 8.0, 6.8, 1.2 Hz, 1H), 4.17 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$ 

157.08, 147.03, 143.92, 134.37, 127.85, 127.45, 126.70, 123.52, 65.81; HRMS (ESI): Calc'd for  $[M+H]^+$  C<sub>9</sub>H<sub>9</sub>N<sub>2</sub>O<sub>2</sub> : 177.0656; found 177.0658.

**quinazolin-4(3***H***)-one(2u)**:<sup>3</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a white solid (17 mg, yield = 78%); Mp.110-112 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  11.99 (s, 1H), 8.27 (ddd, *J* = 8.0, 1.6, 0.8 Hz, 1H), 8.02 (s, 1H), 7.79-7.70 (m, 2 H), 7.50 (ddd, *J* = 8.4, 6.8, 1.2 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  162.28, 148.73, 144.06,

134.37, 127.36, 126.93, 126.14, 122.64, 39.95, 39.74, 39.53.

8-methyl-3-phenylquinazolin-4(3H)-one(2v):<sup>13</sup> The title compound was prepared according to the general



procedure C on a 0.15 mmol scale to obtain as a light yellow solid (27 mg, yield = 77%); Mp.109-111 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.22 (ddd, *J* =8.0, 1.6, 0.8 Hz, 1H), 8.15 (s, 1H), 7.64 (ddd, *J* = 7.2, 1.6, 0.8 Hz, 1H), 7.57-7.53 (m, 2H), 7.50-7.47 (m, 1H), 7.45-7.41 (m, 3H), 2.66 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  161.06, 146.39, 144.81,

137.56, 135.97, 135.24, 129.91, 129.59, 128.99, 127.18, 126.94, 124.84, 122.31, 17.46.


6-methoxy-3-phenylquinazolin-4(3*H*)-one (2w):<sup>14</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a white solid (30 mg, yield = 79%); Mp.160-162 °C; Mp: C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.04 (s, 1H), 7.72 (dd, *J* = 8.0, 3.2 Hz, 2H), 7.58-7.54 (m, 2H), 7.52-7.50 (m, 1H), 7.44-7.38 (m, 3H), 3.94 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.61, 159.00, 143.96, 142.36, 137.61, 129.59, 129.11, 129.03, 128.91,

126.98, 125.22, 124.63, 106.59, 55.86.

**7-nitro-3-phenylquinazolin-4**(*3H*)-one (2x): The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a white solid (30 mg, yield = 74%); Mp.225-227 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.61 (d, *J* = 2 Hz, 1H),8.53 (dd, *J*=8.4, 0.4 Hz, 1H), 8.31 (dd, *J* = 8.8, 2.4 Hz, 1H), 8.23 (s, 1H), 7.59-7.53 (m, 3H), 7.44-7.42 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  159.54, 151.61, 148.47, 148.03, 136.72, 129.87, 129.63,

129.15, 126.75, 126.57, 123.24, 121.30; HRMS (ESI): Calc'd for  $[M+H]^+$  C<sub>14</sub>H<sub>10</sub>N<sub>3</sub>O<sub>3</sub> : 268.0715; found 268.0716.


7-fluoro-3-phenylquinazolin-4(3H)-one (2y):<sup>3</sup> The title compound was prepared according to the general



procedure C on a 0.15 mmol scale to obtain as a white solid (28 mg, yield = 78%); Mp.180-182 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.39(dd, *J* = 8.8, 6.0 Hz, 1H), 8.14 (s, 1H), 7.57-7.48 (m, 3H), 7.42-7.40 (m, 3H), 7.28-7.23 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100


MHz)  $\delta$  167.79, 165.26 (d,  $J_F$  =253.5 Hz), 160.03, 150.11, 149.98 (d,  $J_F$  =13 Hz), 147.26, 137.16, 130.00, 129.89, 129.68, 129.25, 129.14, 129.03, 126.92, 125.28, 123.63, 120.99, 119.87, 119.06, 116.48, 116.25 (d,  $J_F$  = 23.2 Hz), 113.15, 112.93(d,  $J_F$  = 21.8Hz).

7-chloro-3-phenylquinazolin-4(3H)-one (2z):<sup>3</sup> The title compound was prepared according to the general



procedure C on a 0.15 mmol scale to obtain as a white solid (35 mg, yield = 89%); Mp.186-188 °C; <sup>1</sup>H NMR(CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.26 (d, J = 8.4 Hz, 1H), 8.13 (s, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.57-7.48 (m, 4H), 7.42-7.40 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 160.11, 148.79, 147.20, 140.78, 137.10, 129.67, 129.25, 128.60, 128.21, 127.14, 126.86, 120.79.

6-bromo-3-phenylquinazolin-4(3H)-one (2a'):<sup>3</sup> The title compound was prepared according to the general




procedure C on a 0.15 mmol scale to obtain as a white solid (34 mg, yield = 76%); Mp.178-180 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.49 (d, J = 2.4 Hz, 1H), 8.12 (s, 1H), 7.88 (dd, J = 8.8, 2.4 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.58-7.48 (m, 3H), 7.42-7.40

(m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 159.56, 146.69, 146.38, 137.74, 137.15, 129.72, 129.69, 129.38, 129.29, 126.87, 123.75, 121.30.

**6-iodo-3-phenylquinazolin-4(3H)-one(2b')**:<sup>3</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as a light yellow solid (38 mg, yield = Ο 73%); Mp.166-168 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.68 (d, J = 2.0 Hz, 1H), 8.12 (s, 2b' 1H), 8.05 (dd, J = 8.8, 2.0 Hz, 1H), 7.57-7.47 (m, 4H), 7.41-7.39 (m, 2H); <sup>13</sup>C NMR

(CDCl<sub>3</sub>, 100 MHz) & 159.28, 147.13, 146.56, 143.34, 137.13, 135.91, 130.06, 129.70, 129.34, 129.27, 127.84, 126.85, 123.91, 92.24.

**3.6-diphenylquinazolin-4(3H)-one (2c')**: The title compound was prepared according to the general procedure




C on a 0.15 mmol scale to obtain as a white solid (36 mg, yield = 80%); Mp.124-126°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.59 (d, J = 2.4 Hz, 1H), 8.14 (s, 1H), 8.06 (dd, J = 8.8, 2.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.71 (dd, J = 3.2, 1.6 Hz, 2H), 7.57 (dd, J = 8.8,

7.2 Hz, 2H), 7.52-7.40 (m, 6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 160.80, 147.00, 145.96, 140.60, 139.43, 137.47, 133.47, 129.65, 129.12, 129.00, 128.08, 127.98, 127.23, 126.98, 125.02, 122.60, 77.31; HRMS (ESI): Calc'd for [M+H]<sup>+</sup> C<sub>20</sub>H<sub>15</sub>N<sub>2</sub>O : 299.1179; found 299.1178.

3-phenylbenzo[g]quinazolin-4(3H)-one (2d'): The title compound was prepared according to the general 0 procedure C on a 0.15 mmol scale to obtain as a white solid (31 mg, yield = 76%); ∠Ph Mp.224-226 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.98 (s, 1H), 8.26 (s, 1H), 8.12-8.08 (m, 2d' 2H). 8.03 (d, J = 8.4 Hz 1H). 7.66 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H). 7.60-7.56 (m, 3H).

7.53-7.46 (m, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 161.25, 145.35, 143.08, 137.60, 136.59, 131.95, 129.66, 129.42, 128.99, 128.87, 128.70, 128.09, 127.09, 126.68, 125.59, 120.81, 109.97; HRMS (ESI): Calc'd for [M+H]<sup>+</sup> C<sub>18</sub>H<sub>13</sub>N<sub>2</sub>O : 273.1021; found 273.1022.

3-(2-hydroxyethyl) quinazolin-4(3H)-one (2e'):<sup>10</sup> The title compound was prepared according to the general



procedure C on a 0.15 mmol scale to obtain as a white solid (24 mg, yield = 83%); Mp.154-155 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.07-8.05 ( m, 2H), 7.65 (ddd, *J* = 8.4, 7.2, 1.6 Hz, 1H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.38-7.34 (m, 1H), 4.09 (t, *J* = 9.6 Hz, 2H),

3.97 (t, *J* = 10.0 Hz, 2H), 3.70 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 161.20, 147.51, 147.39, 134.29, 127.20, 126.77, 126.35, 121.54, 63.61, 60.06, 49.64.


**3-(2-(1H-indol-3-yl)ethyl)quinazolin-4(3***H***)-one (2f'):<sup>15</sup> The title compound was prepared according to the general procedure C on a 0.15 mmol scale to obtain as alight yellow solid (31mg, yield = 71%); Mp.162-164 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) \delta 8.36 (ddd,** *J* **= 8.0, 1.6, 0.4 Hz, 1H), 8.20 (s, 1H), 7.73 (ddd,** *J* **= 8.0, 6.8, 1.6 Hz, 1H), 7.66-7.62 (m, 2H), 7.53-7.50 (m, 2H), 7.36-7.33 (m, 1H), 7.20 (ddd,** *J* **= 8.0, 1.6, 0.4 Hz, 1H), 7.12 (ddd,** *J* **= 8.0, 7.2, 1.2 Hz, 1H), 6.86 (d,** *J* **= 2.4 Hz, 1H), 4.29 (t,** *J* **= 6.8 Hz, 2H), 3.26 (dd,** *J* **= 7.2, 6.0 Hz, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) \delta 161.08, 148.10, 146.69, 136.41, 134.11, 127.31, 127.09, 126.77, 126.60, 122.74, 122.34, 122.06,** 

119.72, 118.34, 111.47, 111.25, 47.51, 24.90.

**2-amino-4-nitro-N-phenylbenzamide** (1x): The title compound was prepared according to the general procedure B on a 1.2 mmol scale to obtain as a yellow solid (205 mg, yield = 66%); Mp.161-163 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.80 (s, 1H), 7.62-7.56 (m, 3H), 7.55 (d, J = 2.0 Hz, 1H), 7.49 (dd, J = 8.4, 2.4 Hz, 1H), 7.41 (ddd, J = 7.6, 4.0, 2.0 Hz, 2H), 7.21 (ddd, J = 7.2, 2.4, 1.2 Hz, 1H), 5.79 (s, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  165.97, 150.33, 149.41, 137.09, 129.18, 128.32, 125.22, 120.79, 120.71, 111.56, 110.76; HRMS (ESI): Calc'd for [M+H]<sup>+</sup> C<sub>13</sub>H<sub>12</sub>N<sub>3</sub>O<sub>3</sub> : 258.0872; found 258.0873.

**2-amino-5-iodo-***N***-phenylbenzamide** (**1b**'): The title compound was prepared according to the general procedure B on a 1.2 mmol scale to obtain as a light yellow solid (300 mg, yield = 72%); Mp.158-160 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.74-7.72 (m, 2H), 7.56-7.54 (m, 2H), 7.47 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.39-7.35 (m, 2H), 7.16(ddd, *J* = 8.4, 2.4, 1.2 Hz, 1H), 6.50 (d, *J* = 8.4 Hz, 1H), 5.50 (s, 2H), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  166.16, 148.32, 140.86, 137.42, 135.47, 129.03, 124.76, 120.67, 119.44, 118.53, 77.31; HRMS (ESI): Calc'd for [M+H]<sup>+</sup> C<sub>13</sub>H<sub>12</sub>IN<sub>2</sub>O : 338.9991; found 338.9988.


4-amino-N-phenyl-[1,1'-biphenyl]-3-carboxamide (1c'): The title compound was prepared according to the



general procedure B on a 1.2 mmol scale to obtain as a light yellow solid (220 mg, yield = 63%); Mp.179-180 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.65 (d, *J* = 2.4 Hz, 1H), 7.57-7.47 (m, 5H), 7.42-7.36 (m, 4H), 7.35-7.28 (m, 2H), 7.14 (t, *J* = 7.6 Hz, 1H), 6.75 (d, *J* =

8.4 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.58, 148.04, 140.27, 137.75, 131.37, 130.24, 129.95, 129.03, 128.97, 128.77, 128.67, 126.62, 126.40, 126.25, 125.77, 124.47, 120.58, 117.86, 116.64; HRMS (ESI): Calc'd for [M+H]<sup>+</sup> C<sub>19</sub>H<sub>17</sub>N<sub>2</sub>O : 289.1335; found 289.1335.


2-((2-hydroxyethyl)amino)-N-phenylbenzamide (1'a):<sup>19</sup> The title compound was prepared according to the



literature procedure on a 0.94 mmol scale to obtain as a yellow liquid (190 mg, yield = 78%); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.84 (ddd, *J* = 8.0, 1.6, 0.4 Hz, 1H), 7.29-7.25 (m, 1H), 7.22-7.17 (m, 2H), 6.75 -6.71 (m, 1H), 6.69 -6.62 (m, 4H), 5.71(s, 2H), 4.49-4.46 (m, 2H), 4.08 (s, 1H), 3.54-3.48 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$   $\delta$ 168.02, 150.56,

147.63, 134.29, 131.13, 129.31, 117.83, 116.69, 116.26, 112.94, 110.34, 62.98, 42.99; HRMS (ESI): Calc'd for  $[M^+H]^+C_{15}H_{17}N_2O_2: 257.12845;$  found 257.12838.


2-formamido-N-phenylbenzamide (7a):<sup>20</sup> The title compound was prepared according to the literature



procedure on a 0.94 mmol scale to obtain as a white solid (170 mg, yield = 75%); Mp.159-161 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  10.60 (s,1H), 8.46-8.43 (m, 2H), 8.33 (d, *J* = 2.0 Hz, 1H), 7.65 -7.58 (m, 3H), 7.43-7.38 (m, 3H), 7.21 (ddd, *J* = 8.4, 2.0, 0.8 Hz, 1H), 7.12 (dt, *J* = 7.6, 1.2 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  167.04, 159.63, 137.83, 137.27,

132.60, 129.15, 126.99, 125.18, 123.65, 122.34, 121.58, 120.65. HRMS (ESI): Calc'd for  $[M^+Na]^+C_{14}H_{12}N_2Na$ O<sub>2</sub> : 263.07910; found 263.07922.

**3-phenyl-2,3-dihydroquinazolin-4(1H)-one** (8a):<sup>21</sup> The title compound was prepared according to the




literature procedure on a 1.2 mmol scale to obtain as a White solid (200 mg, yield = 72%); Mp.164-166 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.04 (d, *J* = 8.0, 1.6 Hz, 1H), 7.42-7.33 (m, 5H), 7.27-2-7.23 (m, 1H), 6.95 (ddd, *J* = 8.0, 7.6, 1.2 Hz, 1H), 6.77-6.75 (m, 1H), 4.99 (s, 2H), 4.49(bs, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  163.22, 147.48, 140.89, 133.51, 129.38,

129.00, 126.43, 125.00, 120.17, 118.20, 115.34, 62.10.

**3-phenylquinazolin-4**(*3H*)-one (6a):<sup>16</sup> The title compound was prepared according to the general procedure D on a 0.15 mmol scale to obtain as a white solid (15 mg, yield = 82%); Mp.173-174 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>+ DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  8.08 (s, 1H), 7.65 (dt, *J* = 6.0, 3.2 Hz, 2H), 7.27-7.22 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  140.76,137.62,121.87, 115.06.

**6-methyl-1***H***-benzo[***d***]imidazole (6b):<sup>16</sup> The title compound was prepared according to the general procedure D on a 0.15 mmol scale to obtain as alight yellow solid (17 mg, yield = 84%);Mp.127-128 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) \delta 8.09 (s, 1H), 7.48 (d,** *J* **= 8.0 Hz, 1H), 7.20 (t,** *J* **= 7.6 Hz, 1H), 7.10 (d,** *J* **= 7.2 Hz, 1H), 5.73 (s, 1H), 2.62 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) \delta 139.99, 137.72, 136.52,** 

 $126.01,\,123.23,\,122.97,\,112.37,\,17.01.$ 




6,7-dimethyl-1*H*-benzo[*d*]imidazole(6c):<sup>17</sup> The title compound was prepared according to the general procedure D on a 0.15 mmol scale to obtain as alight yellow solid (19 mg, yield = 87%); Mp.193-194 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.03 (s, 1H), 7.83 (s, 1H), 7.39 (d, J = 7.2 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 2.52 (s, 3H), 2.39 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  140.30,

137.81, 135.84, 129.73, 124.66, 122.96, 112.08, 19.08, 13.69.



**5,6-dimethyl-1***H***-benzo**[*d*]**imidazole** (**6d**):<sup>16</sup> The title compound was prepared according to the general procedure D on a 0.15 mmol scale to obtain as alight vellow solid (17 mg, vield = 77%); Mp.198-199 °C;<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.00 (s, 1H), 7.73 (s, 1H), 7.42 (s, 2H), 2.35 (s, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 139.93, 136.12, 131.84, 115.43, 20.31.

**5-chloro-1***H***-benzo[***d***]imidazole (6e):<sup>16</sup> The title compound was prepared according to the general procedure D** 



on a 0.15 mmol scale to obtain as alight yellow solid (20 mg, yield = 87%); Mp.112-113 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>+DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  8.07 (s, 1H), 7.64 (d, J = 1.6 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 7.23 (dd, J = 8.8, 2.0 Hz, 1H); <sup>13</sup>C NMR (DMSO, 100 MHz)  $\delta^{13}$ C NMR (101

MHz, CDCl<sub>3</sub>) § 141.84, 138.40, 136.53, 128.09, 123.05, 116.32, 115.23.


**methyl** 1*H*-benzo[*d*]**imidazole-5-carboxylate** (**6f**):<sup>16</sup> The title compound was prepared according to the general Ö procedure D on a 0.15 mmol scale to obtain as alight yellow solid (23 mg, yield = 88%); Ò Mp.133-134 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.40 (d, J =0.8 Hz, 1H), 8.17 (s, 1H), 7.98 6f (dd, J = 8.8, 1.6 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 3.94 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.56, 143.12, 124.27, 123.76,118.160, 114.818, 51.94.

5-nitro-1*H*-benzo[*d*]imidazole (6g):<sup>16</sup> The title compound was prepared according to the general procedure D O<sub>2</sub>N on a 0.15 mmol scale to obtain as a dark brown solid (18 mg, yield = 74%); Mp. 202-203 °C;<sup>1</sup>H NMR (CDCl<sub>3</sub>+DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  8.56 (d, J = 1.6 Hz, 1H), 8.23 (s, 1H), 8.14 6g (dd, J = 9.2, 2.4 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>+DMSO, 100 MHz)  $\delta$ 

145.29, 142.67, 117.35, 113.73, 62.99, 57.86.


#### (4) Kinetic Studies

#### (a) Reaction with Deuterated Ethylene Glycol




To an oven dried sealed tube was charged **1a** (30 mg, 0.14 mmol), EG D<sub>4</sub>: H<sub>2</sub>O (9:1) and TsOH. H<sub>2</sub>O (0.15 mmol) and allowed to stir at 110 °C for 12 h. Then the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The obtained crude was purified using column chromatography by eluting from hexane to 20% ethyl acetate/hexane to afford pure quinazolin-4(3*H*)-ones **2a** in 72% as a white solid (22 mg); Mp.137-138 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  8.39- 8.36 (m, 1H), 8.13 (s, 0.21H), 7.82-7.76 (m, 2H), 7.58-7.54 (m, 3H), 7.52-7.48 (m, 1H), 7.45-7.42 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  160.72, 147.82, 146.04, 137.39, 134.55, 134.45, 134.34, 129.61, 129.08, 127.62, 127.53, 127.14, 127.02, 126.94, 122.33, 109.95; HRMS (ESI): Calc'd for [M+H]<sup>+</sup> C<sub>14</sub>H<sub>10</sub>DN<sub>2</sub>O : 224.0930; found 224.0928.


### Partial Control of Con




#### (b) Procedure for Parallel KIE Experiment:




To an oven dried sealed tube was charged **1a** (30 mg, 0.14 mmol), ethylene glycol (EG):  $H_2O$  (9:1) and TsOH.  $H_2O$  (0.15 mmol) and allowed to stir at 110° C for 2 h. Then the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The yield of the compound was determined by using 1, 3, 5-trimethoxy benzene (4.6 mg) as an internal standard.






To an oven dried sealed tube was charged **1a** (30 mg, 0.14 mmol), ethylene glycol (EG): H<sub>2</sub>O (9:1) and TsOH. H<sub>2</sub>O (0.15 mmol) and allowed to stir at 110  $^{\circ}$ C for 2 h. Then the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The yield of the compound was determined by using 1, 3, 5-trimethoxy benzene (4.7 mg) as an internal standard.




Parallel KIE ratio  $K_H/K_D = 1.94$ 

#### (c) Competitive KIE Experiment:




To an oven dried sealed tube was charged **1a** (30 mg, 0.14 mmol), EG + EG-D<sub>4</sub> (1:1): H<sub>2</sub>O (9:1) and TsOH. H<sub>2</sub>O (0.15 mmol) and allowed to stir at 110 °C for 5 h. Then the reaction mixture was cooled to room temperature and diluted with 5.0 mL of water. The water layer was extracted with (3X10 mL) of ethyl acetate and the combined ethyl acetate layer was given brine wash (1X10 mL). The final ethyl acetate layer was dried over sodium sulfate and concentrated under reduced pressure to get the crude compound. The yield of the compound was determined by using 1, 3, 5-trimethoxy benzene (4.2 mg) as an internal standard.




# (5) Plausible reaction mechanism using 2-methoxy ethanol as methine source for the synthesis of benzimidazole:

Initial oxidation of 2-methoxy Ethanol with TsOH.H<sub>2</sub>O under O<sub>2</sub> atmosphere generated the methyl oxoacetate intermediate **b** via the formation of Methyl glycolate intermediate **a**. Then the compound **b** underwent condensation reaction with compound **5** to form the imine intermediate **c**. Intramolecular annulation of intermediate **c** resulted in the formation of methyl 2,3-dihydro-1*H*-benzo[*d*]imidazole-2-carboxylate **d** followed by hydrolysis to get **e**. Thermal decarboxylation of **e** resulted in penultimate product **f**. Aerobic oxidation of compound **f** gave the desired 1*H*-benzo[*d*]imidazole derivatives.




### (6) Plausible reaction mechanism using Dioxane as Methine Source for the synthesis of 4(3H)quinazolinones:

Initial oxidation of 1,4-dioxane with TsOH.H<sub>2</sub>O under O<sub>2</sub> atmosphere generated the 2-hydroperoxy-1, 4dioxane intermediate **A**. It is known that under O<sub>2</sub> condition intermediate **A** will cleave to several fragments such as 1,4-dioxane-2-one, glycolic acid, glyoxylic acid and formic acid.<sup>18</sup> Then the Glyoxylic acid **C** underwent condensation reaction with compound **1** to form the imine intermediate **D**. Intramolecular annulation of intermediate **D** resulted in the formation of 4-oxo-1,2,3,4tetrahydroquinazoline-2-carboxylic acid **E**. Thermal decarboxylation of **E** resulted in penultimate product **8**. Aerobic oxidation of compound **8** gave the desired 4(3*H*)-quinazolinones derivatives.



## 7) X-Ray Analysis Data







Table S1. Crystal data and structure refinement for 2a.

Identification code	2a		
Empirical formula	$C_{14}H_{10}N_2O$		
Formula weight	222.24		
Temperature	297(2) K		
Wavelength	0.71073 Å		
Crystal system	Monoclinic		
Space group	P 21/c		
Unit cell dimensions	a = 12.1056(8)  Å	a= 90°.	
	b = 7.8020(5)  Å	b= 97.574(5)°.	
	c = 11.6256(6)  Å	g = 90°.	
Volume	1088.43(11) Å <sup>3</sup>		
Z	4		
Density (calculated)	1.356 Mg/m <sup>3</sup>		
Absorption coefficient	0.088 mm <sup>-1</sup>		
F(000)	464		
Crystal size	0.53 x 0.40 x 0.24 mm <sup>3</sup>		
Theta range for data collection	3.11 to 29.18°.		
Index ranges	-9<=h<=16, -8<=k<=10, -15<=l<=15		
Reflections collected	5091		
Independent reflections	2537 [R (int) = 0.0291]		
Completeness to theta = $26.00^{\circ}$	100.0 %		
Absorption correction	Semi-empirical from equivalents		
Max. and min. transmission	1.00000 and 0.93253		
Refinement method	Full-matrix least-squares on F <sup>2</sup>		
Data / restraints / parameters	2537 / 0 / 154		
Goodness-of-fit on F <sup>2</sup>	1.012		
Final R indices [I>2sigma (I)]	R1 = 0.0537, wR2 = 0.1163		
R indices (all data)	R1 = 0.0957, wR2 = 0.1399		
Largest diff. peak and hole	0.154 and -0.209 e.Å <sup>-3</sup> 24		








Table S2. Crystal data and structure refinement for <b>2h</b> .					
Identification code	2h				
Empirical formula	C <sub>14</sub> H <sub>9</sub> FNO				
Formula weight	240.23				
Temperature	297(2) K				
Wavelength	0.71073 Å				
Crystal system	Monoclinic				
Space group	P 21/c				
Unit cell dimensions	a = 12.4895(9)  Å	a= 90°.			
	b = 7.7667(5) Å	b= 96.718(6)°.			
	c = 11.5802(6) Å	$g = 90^{\circ}$ .			
Volume	1115.59(12) Å <sup>3</sup>				
Z	4				
Density (calculated)	1.430 Mg/m <sup>3</sup>				
Absorption coefficient	0.104 mm <sup>-1</sup>				
F(000)	496				
Crystal size	0.42 x 0.38 x 0.37 mm <sup>3</sup>				
Theta range for data collection	3.09 to 29.12°.				
Index ranges	-11<=h<=16, -10<=k<=10, -15<=l<=9				
Reflections collected	5038				
Independent reflections	2592 [R(int) = $0.0629$ ]				
Completeness to theta = $26.00^{\circ}$	99.8 %				
Absorption correction	Semi-empirical from equivalents				
Max. and min. transmission	1.00000 and 0.77825				
Refinement method	Full-matrix least-squares on F <sup>2</sup>				
Data / restraints / parameters	2592 / 0 / 163				
Goodness-of-fit on F <sup>2</sup>	1.028				
Final R indices [I>2sigma(I)]	R1 = 0.0659, wR2 = 0.1548				
R indices (all data)	R1 = 0.0998, $wR2 = 0.1854$				
Largest diff. peak and hole	0.249 and -0.296 e.Å <sup>-3</sup>				


#### (8) References


- 1. R. Cheng, T. Guo, D. Zhang-Negrerie, Y. Du, K. Zhao, Synthesis 2013, 45, 2998.
- 2. T. V. Nguyen, M. S. Blackledge, E. A. Lindsey, B. M. Minrovic, D. F. Ackart, A. B. Jeon, A. Obregon-Henao, R. J. Melander, R. J. Basaraba, C. Melander, *Angew. Chem., Int. Ed.* **2017**, *56*, 3940.
- 3. S. Mukhopadhyay, D. S. Barak, S. Batra, Eur. J. Org. Chem., 2018, 22, 2784.
- 4. L. Xu, Y. Jiang, D. Ma, Org. Lett., 2012, 14, 1150.
- 5. S. Ambethkar, M. Kalaiselvi, V. Padmini, N. Bhuvanesh, Chemistry Select., 2017, 2, 5329.
- 6. Y. N. Mabkhot, M. S. Al-Har, A. Barakat, F. D. Aldawsari, Molecules. 2014, 19, 8725.
- 7. K. R. Rao, A. Raghunadh, R. Mekala, S. B. Meruva, T. V. Pratap, T. Krishna, D. Kalita, E. Laxminarayana,
  B. Prasad, M. Pal, *Tetrahedron Lett.*, 2014, 55, 6004.
- 8. G. Aridoss, K. K. Laali. Eur, J. Org. Chem., 2011, 15, 2827.
- 9. E. Deau, D. Hedou, E. Chosson, V. Levacher, T. Besson, Tetrahedron Lett., 2013, 54, 3518.
- 10. P. Punthasee, A. Vanitcha, S. Wacharasindhu, Tetrahedron Lett., 2010, 51, 1713.
- 11. D. Kumar, S. R. Vemula, G. R. Cook, Green Chem., 2015, 17, 4300.
- 12. D. Hedou, E. Deau, C. Dubouilh-Benard, M. Sanselme, A. Martinet, E. Chosson, V. Levacher, T. Besson, *Eur. J. Org. Chem.*, **2013**, *33*, 7533.
- 13. D. N. Garad, S. B. Mhaske, J. Org. Chem., 2017, 82, 10470.
- 14. Y. Bao, Y. Yan, K. Xu, J. Su, Z. Zha, Z. Wang, J. Org. Chem., 2015, 80, 4736.
- 15. W. R. Bowman, M. R. J. Elsegood, T. Stein, G. W. Weaver, Org. Biomol. Chem., 2007, 5, 103.
- 16. X. Gao, B. Yu, Q. Mei, Z. Yang, Y. Zhao, H. Zhang, L. Hao, Z. Liu, New J. Chem., 2016, 40, 8282.
- 17. Z. Liu, H. Li, Q. Zhao, J. Shen, Heterocycles 2008, 75, 1907.
- 18. A. B. Weinstein, S. S. Stahl, Catal. Sci. Technol., 2014, 4, 4301.
- 19. R. Lisciani, S. Lembo, S. Cozzolino, M.I. Larotonda, C. Silipo, A. Vittoria *Farmaco Ed. Sci.*,**1986**, *41*, 89.


- 20. M. R. Mutra, G. K. Dhandabani, J. -J. Wang, Adv. Synth. Catal., 2018, 360, 3960.
- 21. M.Dabiri, P. Salehi, M. Baghbanzadeh, Monatshefte fuer Chemie., 2007, 138, 1191-1194.
























#### Paratella (1997) Paratella (1





### R 8, 335 8, 8, 335 8, 8, 338 8, 348





















2.462 2.456 2.282 2.282 1.810 1.810 1.791 1.791 1.791 1.695


Solvent CDCl<sub>3</sub> Spectrometer Frequency 400.40













































### 7.557 7.555 7.555 7.555 7.515 7.499 7.499 7.414 7.414




210 200 110 100 f1 (ppm) -10 












### 8.088 7.664 7.664 7.649 7.641 7.541 7.541 7.253 7.253 7.253 7.253 7.253 7.253 7.253

Solvent CDCl<sub>3</sub> Spectrometer Frequency 400.40




20 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)







210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)




Solvent CDCl<sub>3</sub> Spectrometer Frequency 400.40
















70 60

-10


20 210 200 190 180 170 160 150 140 130 120 110 100 f1 (ppm)






### 77, 208 77, 59


Solvent CDCl<sub>3</sub> Spectrometer Frequency 400.40





## 7.224 7.233 7.230 7.211 7.211 7.211 7.211 7.196


---0.012



















7.853 7.853 7.853 7.853 7.853 7.853 7.853 7.834 7.8347 7.8347 7.

Solvent CDCl<sub>3</sub> Spectrometer Frequency 400.40

## 








Spectrometer Frequency 100.69





B 4463 B 4463 B 4463 B 4450 B 4332 B

Solvent CDCl<sub>3</sub> Spectrometer Frequency 400.40

# 

0000.0-----

